Your Health, We Care
Zydelig, in combination with rituximab, is indicated for the treatment of patients with relapsed chronic lymphocytic leukemia who are considered suitable for rituximab monotherapy due to other comorbidities.
Zydelig is not indicated and is not recommended for first-line treatment in any patients, including those with chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, and other indolent non-Hodgkin lymphomas.
Zydelig is not indicated and is not recommended for use in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with follicular lymphoma, small lymphocytic lymphoma, and other indolent non-Hodgkin lymphomas.
FDA，2022.02
